Yves Bikorimana: What Every Lab and Clinician Should Know on Pseudothrombocytopenia
Yves Bikorimana, CEO at MedData-Rwanda and Lab Scientist at The University Teaching Hospital of Kigali-Chuk, shared a post on LinkedIn.
“Pseudothrombocytopenia (PTCP): What Every Lab and Clinician Should Know
Pseudothrombocytopenia is a laboratory artifact where platelet counts appear falsely low on automated analyzers, despite the patient having a normal platelet count in vivo. Importantly, it is not a true clinical thrombocytopenia and does not increase bleeding risk.
Why does it happen?
The most common cause is EDTA-dependent platelet clumping. In some individuals, EDTA (the anticoagulant used in routine CBC tubes) exposes platelet surface antigens, leading to antibody-mediated platelet aggregation. Automated analyzers then misinterpret these clumps as leukocytes or exclude them entirely, resulting in a falsely low platelet count.
Key Laboratory Features
- Low platelet count on automated CBC
- Platelet clumps visible on peripheral blood smear
- Normal platelet count when blood is collected in:
- Sodium citrate
- Heparin
- Magnesium sulfate (rarely used but effective)
Clinical Significance
- Patients are usually asymptomatic
- No bleeding manifestations
- Can be mistaken for serious conditions like:
- Immune thrombocytopenic purpura (ITP)
- Bone marrow disorders
- Drug-induced thrombocytopenia
Why recognition matters
Failure to identify PTCP can lead to:
- Unnecessary platelet transfusions
- Inappropriate treatments (e.g., steroids, IVIG)
- Delays in surgeries or invasive procedures
- Patient anxiety and misdiagnosis
Best Practice Approach
- Always review the peripheral smear when thrombocytopenia is detected
- Repeat platelet count using an alternative anticoagulant
- Correlate laboratory findings with clinical presentation
Take-home message
Pseudothrombocytopenia highlights the importance of laboratory-clinical correlation and the continued value of manual smear examination in modern diagnostics.”
Find the latest updates on Hemostasis Today.
-
May 27, 2026, 13:10Amos Gitonga M: Global Partnerships Supporting Hemophilia and Sickle Cell Care in Africa
-
May 27, 2026, 09:58Omid Seidizadeh: Take The EAHAD Survey on Access to Diagnosis and Treatment for VWD Europe
-
May 27, 2026, 09:51Richard Benjamin: RedeS Phase III Trial Reaches Major Milestone in Advancing Pathogen-Reduced RBCs for Transfusion
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK